Humana Inc. saw its stock plunge more than 20% on Tuesday, falling to approximately $206 per share—a level the company hasn't visited since 2017. The collapse came after the Trump administration proposed a Medicare Advantage payment increase of just 0.09% for 2027, shattering Wall Street expectations of a 5-6% rate hike.

The announcement effectively erased eight years of share price appreciation in a single trading session, crystallizing fears that have been building across the health insurance sector about the sustainability of Medicare Advantage economics in a post-pandemic environment.

The Rate Shock Explained

The Centers for Medicare & Medicaid Services (CMS) unveiled its preliminary 2027 rate notice on Monday evening, catching industry observers off guard with its severity. The proposed 0.09% increase represents a dramatic departure from the 5.06% bump insurers received for 2026.

"This proposal aims to strengthen payment accuracy and modernize risk adjustment while protecting taxpayers from unnecessary spending."

— Dr. Mehmet Oz, CMS Administrator

The rationale behind the minimal increase centers on concerns that Medicare Advantage plans have been overpaid relative to traditional Medicare. Independent analyses have suggested that risk adjustment practices—the mechanism by which sicker patients generate higher payments—have been exploited to inflate reimbursements beyond appropriate levels.

Why Humana Is Hit Hardest

Among major health insurers, Humana faces the most concentrated exposure to Medicare Advantage economics. The Louisville-based company derives roughly 80% of its revenue from Medicare Advantage plans, compared to more diversified competitors who have broader commercial insurance and pharmacy benefit management operations.

This concentration, which drove Humana's outperformance during the Medicare Advantage enrollment boom of the 2010s, has become a liability as the program's economics come under pressure.

The Medical Cost Crisis

The rate freeze arrives at precisely the wrong moment for Medicare Advantage insurers. Medical costs have been running significantly above expectations throughout 2025, driven by:

  • Deferred care catch-up: Seniors who delayed procedures during the pandemic have been seeking care at elevated rates
  • GLP-1 medications: Expensive weight-loss and diabetes drugs like Ozempic and Wegovy have created unexpected pharmacy cost pressures
  • Staffing costs: Healthcare labor shortages have pushed wages higher across the medical system
  • Supplemental benefits: Competitive pressure has forced insurers to offer increasingly generous benefits to attract enrollees

With costs rising and reimbursement flat, insurers face difficult choices: absorb the margin compression, reduce benefits to members, or exit certain markets entirely.

Sector-Wide Carnage

Humana's decline, while the most severe, was part of a broader rout across health insurance stocks:

  • UnitedHealth Group: Dropped more than 19% after also reporting weaker-than-expected 2026 revenue guidance
  • CVS Health: Fell 13% on exposure through its Aetna Medicare Advantage business
  • Elevance Health: Tumbled approximately 11%
  • Centene: Declined more than 7%

Collectively, the Medicare Advantage-focused insurers lost tens of billions of dollars in market capitalization in a single session—one of the worst days for the healthcare sector since the onset of the COVID-19 pandemic.

The Path Forward

The proposed rates are not final. CMS will accept industry comments before issuing a final rate notice in early April, and historically, preliminary proposals have been adjusted upward after pushback from insurers and their congressional allies.

However, the policy direction under the current administration appears focused on reining in Medicare Advantage spending growth. Dr. Oz, a prominent television personality before becoming CMS Administrator, has made controlling healthcare costs a centerpiece of his tenure.

Strategic Options for Humana

Humana's management will need to address the rate shock when it reports fourth-quarter earnings in the coming weeks. Potential responses include:

  • Benefit reductions: Scaling back supplemental benefits like dental, vision, and hearing coverage
  • Market exits: Withdrawing from unprofitable geographic markets
  • Premium increases: Raising costs for members, though this risks enrollment losses
  • Cost cutting: Administrative and operational expense reductions
  • M&A: Pursuing scale through acquisition or positioning itself as an acquisition target

What Investors Should Consider

The Medicare Advantage rate shock raises fundamental questions about the sector's investment thesis. For years, insurers benefited from favorable demographics as the baby boom generation aged into Medicare eligibility, combined with generous government reimbursement rates designed to encourage private sector participation.

Both tailwinds may be fading. Enrollment growth is slowing as early adopters have already enrolled, and the government appetite for above-market payments appears to be diminishing regardless of which party controls Washington.

For Humana specifically, the stock's return to 2017 levels despite eight years of earnings growth suggests the market is pricing in a fundamentally different—and less attractive—future for Medicare Advantage economics. Whether that pessimism proves justified will depend largely on the April final rate notice and the company's ability to adapt to a more challenging reimbursement environment.